Aghemo A, Persico M, D'Ambrosio R, Andreoni M, et al. Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study. PLoS One 2023;18:e0280165.
PMID: 36730135